Lincoln Capital Corp acquired a new stake in Mallinckrodt PLC (NYSE:MNK) in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 20,000 shares of the company’s stock, valued at approximately $48,000.
A number of other hedge funds also recently made changes to their positions in MNK. Meeder Asset Management Inc. raised its holdings in shares of Mallinckrodt by 4.6% during the second quarter. Meeder Asset Management Inc. now owns 45,088 shares of the company’s stock valued at $414,000 after acquiring an additional 2,003 shares in the last quarter. Parallel Advisors LLC grew its stake in Mallinckrodt by 1,239.3% in the second quarter. Parallel Advisors LLC now owns 3,000 shares of the company’s stock worth $28,000 after purchasing an additional 2,776 shares during the period. Coastal Capital Group Inc. purchased a new stake in Mallinckrodt in the second quarter worth $31,000. Swiss National Bank grew its stake in Mallinckrodt by 2.3% in the second quarter. Swiss National Bank now owns 155,300 shares of the company’s stock worth $1,426,000 after purchasing an additional 3,500 shares during the period. Finally, NumerixS Investment Technologies Inc grew its stake in Mallinckrodt by 30.3% in the second quarter. NumerixS Investment Technologies Inc now owns 15,900 shares of the company’s stock worth $146,000 after purchasing an additional 3,700 shares during the period.
Several equities research analysts recently weighed in on MNK shares. BMO Capital Markets reaffirmed a “market perform” rating on shares of Mallinckrodt in a research note on Thursday, September 5th. Barclays set a $5.00 price target on Mallinckrodt and gave the stock a “hold” rating in a research note on Tuesday, September 10th. SunTrust Banks reduced their price target on Mallinckrodt to $7.00 and set a “positive” rating on the stock in a research note on Monday, August 12th. Jefferies Financial Group set a $2.00 price target on Mallinckrodt and gave the stock a “hold” rating in a research note on Friday, September 6th. Finally, Morgan Stanley set a $5.00 price target on Mallinckrodt and gave the stock a “hold” rating in a research note on Friday, August 9th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $10.19.
Mallinckrodt (NYSE:MNK) last released its earnings results on Tuesday, November 5th. The company reported $2.07 EPS for the quarter, topping analysts’ consensus estimates of $1.98 by $0.09. Mallinckrodt had a positive return on equity of 24.36% and a negative net margin of 111.44%. The firm had revenue of $743.70 million for the quarter, compared to analysts’ expectations of $770.56 million. During the same period in the prior year, the firm posted $2.10 earnings per share. The company’s quarterly revenue was down 7.0% on a year-over-year basis. On average, analysts anticipate that Mallinckrodt PLC will post 8.59 earnings per share for the current year.
Mallinckrodt Company Profile
Mallinckrodt plc, together with its subsidiaries, develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands, and Specialty Generics and Amitiza.
Featured Article: What are the benefits of momentum investing?
Want to see what other hedge funds are holding MNK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mallinckrodt PLC (NYSE:MNK).
Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.